论文部分内容阅读
目的 探讨早产儿出生后不同时间开始应用沐舒坦预防肺透明膜病 (HMD)的效果。方法 15 0例胎龄≤ 36周的早产儿入院后均给予沐舒坦 30mg·kg- 1 ·d- 1 ,分 2～ 4次静脉滴注 ,并分别按用药距出生时间分为～ 1h、～ 6h、～ 12h、～ 2 4h 4组 ,观察其发生HMD的情况 ,并与对照组进行比较分析。结果 1)观察组 15 0例中发生HMD 14例 (9 33% ) ,对照组 15 0例中发生HMD 2 6例 (16 6 7% ,P <0 0 5 ) ;2 )出生后不同时间开始应用沐舒坦 ,在 1h内及 1～ 6h用药者 ,HMD的发生率分别为 3 2 2 %和 6 0 6 % ,与对照组比较均P <0 0 5 ;而 6～ 12h及 12～ 2 4h用药者 ,HMD的发生率分别率为 14 81%及 19 2 3% ,与对照组比较均P >0 0 5。结论 早产儿出生后及早应用沐舒坦预防HMD有良好效果 ,但用药时机必须掌握在出生后 6h内 ,超过 6h则效果不显著
Objective To investigate the effect of ambroxol on the prevention of hyaline membrane disease (HMD) in preterm infants at different times after birth. Methods 150 preterm infants with gestational age ≤ 36 weeks were given mucosolvan 30 mg · kg-1 · d-1 intravenously in 2 ~ 4 times intravenously. The preterm infants were divided into ~ 1h ~ 6h, ~ 12h, ~ 24h 4 groups were observed the occurrence of HMD, and compared with the control group. Results 1) There were 14 cases (9 33%) of HMD in observation group and 26 cases of HMD in control group (16 6 7%, P <0 05); 2) At different time after birth The application rate of mucosolvan, 1h and 1 ~ 6h, the incidence of HMD were 32.2% and 60.6%, respectively, compared with the control group, P <0 05; while 6-12 hours and 12-24 hours The incidence of HMD was 14.81% and 19.23%, respectively, compared with the control group (P> 0.05). Conclusion Early application of ambroxol in the prevention of HMD after birth in preterm infants has a good effect, but the timing of medication must be controlled within 6h after birth, while the effect is not significant after 6h